Literature DB >> 2244794

Delta sleep ratio. A biological correlate of early recurrence in unipolar affective disorder.

D J Kupfer1, E Frank, A B McEachran, V J Grochocinski.   

Abstract

Slow wave sleep abnormalities have long been described in depression but were considered to be nonspecific indicators of psychopathology. Computerized techniques, including amplitude frequency measures and spectral analyses, are permitting new approaches to the examination of delta sleep. Early studies suggested that many depressed patients demonstrate lower delta wave intensity during the first non-rapid eye movement period than the second one. This finding, prominent in middle-aged depressed patients, has led to an examination of the ratio between the first and second non-rapid eye movement periods. This delta sleep measure seems to be a more robust predictor of recurrence than rapid eye movement latency. Analysis of data on 74 patients in a long-term maintenance treatment study for a minimum of 24 months demonstrates that the delta sleep ratio can predict survival time following discontinuation of drug treatment. Individuals with a high delta sleep ratio remain clinically remitted five times longer than those with a low delta sleep ratio.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2244794     DOI: 10.1001/archpsyc.1990.01810240020004

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  35 in total

1.  Sleep Disturbances in Pediatric Depression.

Authors:  Uma Rao
Journal:  Asian J Psychiatr       Date:  2011-12

Review 2.  Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Authors:  Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

3.  Relationships between menopausal and mood symptoms and EEG sleep measures in a multi-ethnic sample of middle-aged women: the SWAN sleep study.

Authors:  Howard M Kravitz; Elizabeth Avery; Maryfran Sowers; Joyce T Bromberger; Jane F Owens; Karen A Matthews; Martica Hall; Huiyong Zheng; Ellen B Gold; Daniel J Buysse
Journal:  Sleep       Date:  2011-09-01       Impact factor: 5.849

Review 4.  An Integrated Model of Slow-Wave Activity and Neuroplasticity Impairments in Major Depressive Disorder.

Authors:  Jennifer R Goldschmied; Philip Gehrman
Journal:  Curr Psychiatry Rep       Date:  2019-03-18       Impact factor: 5.285

Review 5.  Psychotherapy: definitions, mechanisms of action, and relationship to etiological models.

Authors:  D A Brent; D J Kolko
Journal:  J Abnorm Child Psychol       Date:  1998-02

6.  Task switching in older adults with and without insomnia.

Authors:  Kristine A Wilckens; Martica H Hall; Kirk I Erickson; Anne Germain; Vishwajit L Nimgaonkar; Timothy H Monk; Daniel J Buysse
Journal:  Sleep Med       Date:  2016-10-21       Impact factor: 3.492

Review 7.  REM sleep abnormalities and psychiatry.

Authors:  J A Fleming
Journal:  J Psychiatry Neurosci       Date:  1994-11       Impact factor: 6.186

8.  Systematic analysis of circadian genes in a population-based sample reveals association of TIMELESS with depression and sleep disturbance.

Authors:  Siddheshwar J Utge; Pia Soronen; Anu Loukola; Erkki Kronholm; Hanna M Ollila; Sami Pirkola; Tarja Porkka-Heiskanen; Timo Partonen; Tiina Paunio
Journal:  PLoS One       Date:  2010-02-18       Impact factor: 3.240

9.  Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy?

Authors:  Alexandre Y Dombrovski; Jill M Cyranowski; Benoit H Mulsant; Patricia R Houck; Daniel J Buysse; Carmen Andreescu; Michael E Thase; Alan G Mallinger; Ellen Frank
Journal:  Depress Anxiety       Date:  2008       Impact factor: 6.505

10.  Polyunsaturated fatty acids moderate the effect of poor sleep on depression risk.

Authors:  Francis E Lotrich; Barry Sears; Robert K McNamara
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2015-11-10       Impact factor: 4.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.